Cargando…
Modeling long-term health and economic implications of new treatment strategies for Parkinson’s disease: an individual patient simulation study
Background: Simulation modeling facilitates the estimation of long-term health and economic outcomes to inform healthcare decision-making. Objective: To develop a framework to simulate progression of Parkinson’s disease (PD), capturing motor and non-motor symptoms, clinical outcomes, and associated...
Autores principales: | Chandler, Conor, Folse, Henri, Gal, Peter, Chavan, Ameya, Proskorovsky, Irina, Franco-Villalobos, Conrado, Yang, Yunyang, Ward, Alex |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Routledge
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8183552/ https://www.ncbi.nlm.nih.gov/pubmed/34122780 http://dx.doi.org/10.1080/20016689.2021.1922163 |
Ejemplares similares
-
Estimated Societal Value of Lecanemab in Patients with Early Alzheimer’s Disease Using Simulation Modeling
por: Tahami Monfared, Amir Abbas, et al.
Publicado: (2023) -
A Path to Improved Alzheimer’s Care: Simulating Long-Term Health Outcomes of Lecanemab in Early Alzheimer’s Disease from the CLARITY AD Trial
por: Tahami Monfared, Amir Abbas, et al.
Publicado: (2023) -
Predicting the Societal Value of Lecanemab in Early Alzheimer’s Disease in Japan: A Patient-Level Simulation
por: Igarashi, Ataru, et al.
Publicado: (2023) -
Cost-Effectiveness of Lisocabtagene Maraleucel Versus Axicabtagene Ciloleucel and Tisagenlecleucel in the Third-Line or Later Treatment Setting for Relapsed or Refractory Large B-cell Lymphoma in the United States
por: Parker, Christopher, et al.
Publicado: (2023) -
The Potential Economic Value of Lecanemab in Patients with Early Alzheimer’s Disease Using Simulation Modeling
por: Tahami Monfared, Amir Abbas, et al.
Publicado: (2022)